Core C: Biospecimen and Pathology Core

核心 C：生物样本和病理学核心

• 批准号: 10468828
• 负责人: STEVEN R ALBERTS
• 金额: $ 27.81万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-10 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10468828
• 关键词: Address; Aliquot; Animal Model; Arizona; Bacterial Artificial Chromosomes; Basic Science; Biliary; Bioinformatics; Biological Specimen Banks; Biometry; Biopsy; Blood; Blood Platelets; Blood specimen; Cancer Model; Cancer Patient; Cell Line; Cessation of life; Characteristics; Cholangiocarcinoma; Cholestasis; Clinic; Clinical; Clinical Data; Clinical Research; Consent; Core Facility; DNA; Data; Databases; Development; Diagnosis; Diagnostic; Dietary History; Disease; Early Diagnosis; Evaluation; Excision; Family; Fibrolamellar Hepatocellular Carcinoma; Florida; Formalin; Freezing; Frozen Sections; Funding; Future; Genes; Genetic; Genomic DNA; Goals; Hepatobiliary; Histology; Human; Immunocompetent; Immunohistochemistry; Individual; Infrastructure; International; Joints; Knock-out; Knockout Mice; Laboratories; Liver; Maintenance; Malignant Neoplasms; Malignant neoplasm of liver; Mayo Clinic Cancer Center; Medical History; Medidata; Molecular Analysis; Molecular Genetics; Neoplasms; Online Systems; Operative Surgical Procedures; Outcome; Paraffin; Paraffin Embedding; Pathologic; Pathology; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Phenotype; Plasma; Prevention strategy; Process; Program Research Project Grants; Recording of previous events; Registries; Research; Research Personnel; Research Project Grants; Resected; Resource Sharing; Resources; Risk Factors; Sampling; Serum; Services; Site; Sleeping Beauty; Specimen; Stains; The Cancer Genome Atlas; Tissue Embedding; Tissue Microarray; Tissues; Toxin; Transgenic Mice; Transgenic Organisms; Translational Research; Tumor stage; Universities; Unresectable; Vision; anticancer research; base; biobank; burden of illness; cancer site; career; data acquisition; demographics; digital imaging; disease registry; early phase clinical trial; genetic analysis; hepatobiliary cancer; improved; liver cancer model; liver transplantation; mouse model; patient derived xenograft model; prevent; programs; prospective; repository; transplant registry; treatment response; tumor; virtual

CORE C BIOSPECIMEN AND PATHOLOGY – PROJECT SUMMARY The Biospecimen and Pathology Core (Core C) will be responsible for accessioning and processing new biospecimens with annotated clinical data to provide the needed biospecimens for the four SPORE translational research projects, for the Developmental Research and Career Enhancement Programs, and for other investigators engaged in hepatobiliary cancer research. Core C will build on the existing International Hepatobiliary Neoplasia Registry and Biorepository, which has been coordinated by Dr. Lewis Roberts since 2001, and collaborate with additional existing biorepositories including the Genetics of Cholestatic Liver Diseases Registry, coordinated by Dr. Konstantinos Lazaridis, the Liver Transplant Registry coordinated by Dr. Kymberly Watt, and the Hepatobiliary Neoplasia Patient Derived Xenograft program which is jointly coordinated by Dr. Mark Truty and Dr. Roberts. Core C will also coordinate with The Fibrolamellar Hepatocellular Carcinoma Biorepository at the Rockefeller University under Dr. Sanford Simon, which will become part of the Core infrastructure. Core C will provide sample accessioning and pathology support for the early phase clinical trials as needed in the SPORE projects. Core C will coordinate with the Mayo Clinic Cancer Center Biospecimen Accessioning and Processing (BAP) Shared Resource to process blood samples to genomic DNA and serum and plasma aliquots, and with the Pathology Research Core (PRC) Shared Resource to provide histology and other tissue-based services, including paraffin and frozen sectioning, immunohistochemistry, tissue microarray (TMA) construction, and digital imaging. Requests for biospecimens will be reviewed by the Biospecimen Access Committee for Hepatobiliary Cancers (BAC-HEP), with priority access for SPORE investigators and consideration given primarily to scientific merit and availability of biospecimens. Input from the Biostatistics and Bioinformatics Core will be included in the evaluation of biospecimen requests. Dr. Torbenson will provide detailed annotation of the SPORE's tissue database for frozen and formalin-fixed paraffin-embedded tissues of all available patients who have had surgical resections for hepatobiliary cancer at Mayo Clinic, as well as for PDXs, a number of which are derived from percutaneous biopsies of patients with intermediate to advanced unresectable and metastatic disease. The availability of PDXs from biopsies of more advanced tumors will help to address the concern that most of the genetic and molecular analyses of liver and biliary tumors performed thus far, including for example, within The Cancer Genome Atlas project (TCGA), has been performed on early stage surgically resected tumors, not on the intermediate to advanced and metastatic stage tumors for which advances in therapy are urgently needed. Dr. Torbenson will also interpret IHC staining and provide other pathology support such as evaluating tumor samples from Sleeping Beauty, transgenic or knockout mouse models of liver and biliary cancer.

核心C生物制品和病理学--项目总结 生物质检和病理核心(核心C)将负责获取和处理新的 带有注释的临床数据的生物检验剂，以提供四个孢子所需的生物检验剂 翻译研究项目，发展研究和职业发展计划，以及 其他从事肝胆癌研究的调查人员。核心C将建立在现有的国际 肝胆管肿瘤登记和生物库，由Lewis Roberts博士协调，自 2001，并与其他现有的生物信息库合作，包括胆汁淤积性肝脏的遗传学 疾病登记处，由Konstantinos Lazaridis博士协调，肝脏移植登记处，由Konstantinos Lazaridis博士协调。 Kymberly Watt和肝胆肿瘤患者联合推出的异种移植计划 由马克·特鲁蒂博士和罗伯茨博士协调。核心C也将与纤维板层协调 洛克菲勒大学由桑福德·西蒙博士领导的肝细胞癌生物库，这将 成为核心基础设施的一部分。核心C将提供样本加入和病理支持 根据孢子项目的需要进行早期临床试验。核心C将与梅奥癌症诊所协调 中心生物样品获取和处理(BAP)共享资源，用于处理血液样本 基因组DNA、血清和血浆等分，并与病理学研究核心(PRC)共享 提供组织学和其他基于组织的服务的资源，包括石蜡切片和冰冻切片， 免疫组织化学、组织微阵列(TMA)构建和数字成像。 生物检疫申请将由肝胆癌生物检疫准入委员会审查 (BAC-HEP)，优先允许孢子调查人员进入，并主要考虑科学价值 以及生物杀虫剂的可获得性。来自生物统计和生物信息学核心的意见将包括在 对生物检疫申请的评价。托本森博士将提供孢子组织的详细注释 所有患者的冰冻和福尔马林固定石蜡包埋组织的数据库 梅奥诊所的肝胆癌手术切除，以及PDX的手术切除，其中一些是衍生的 从中晚期不可切除和转移性疾病患者的经皮活检。 从更晚期的肿瘤活检组织中获得PDX将有助于解决人们对大多数 迄今对肝脏和胆道肿瘤进行的遗传和分子分析，包括 癌症基因组图谱计划(TCGA)已经在早期手术切除的肿瘤上进行，而不是 论亟待治疗进展的中晚期和转移性肿瘤 需要的。托本森博士还将解释IHC染色，并提供其他病理学支持，如评估 来自睡美人、转基因或基因敲除小鼠的肝癌和胆道癌模型的肿瘤样本。